Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). METHODS: We recruited 301 consecutive patients who had AD without CVD (mean age 71.7 years; 69.4% women; first Mini-Mental State Examination [MMSE] mean score 21.6; mean follow-up 2.3 years), who had attended a memory clinic between 1997 and 2003. VRF sought were high blood pressure, dyslipidemia, diabetes mellitus, tobacco smoking, and atherosclerotic disease. Only 21 patients (7.0%) had no VRF. Others were classified as having no VRF treated (n = 72; 25.7%), some VRF treated (n = 119; 42.5%), or all VRF treated (n = 89; 31.8%). We compared MMSE progression over time among these 3 groups using a mixed random effects regression model. RESULTS: Baseline MMSE scores were similar in the 3 groups. With adjustment for confounding factors, MMSE progression over time differed significantly between groups (p = 0.002). Patients with all their VRF treated declined less than those with none of their VRF treated. Those with some VRF treated tended to have an intermediate decline. CONCLUSIONS: In patients who have Alzheimer disease without CVD, treatment of vascular risk factors (VRF) is associated with a slower decline in Mini-Mental State Examination score. Randomized controlled trials are needed to confirm this association, but our data suggest that dementia should not prevent treatment of VRF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and may delay disease progression (Deschaintre et al., 2009), at least early in the disease course (Richard et al., 2010).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Deschaintre et al., 2009
In the citing paper
“The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“Of individuals age 70 years or older, 20% to 40% without cognitive impairment have biomarker or autopsy evidence of AD pathology 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages. 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Cited by
Items 101–200 of 237
de Oliveira, F. F., Pereira, F. V., Pivi, G. A. K., Smith, M. D. A. C., & Bertolucci, P. H. F. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1396986 · Cited by 28
“nitive decline for patients with AD [19], anti-hypertensive treatment in particular does not seem to have the same”
BackgroundRosengarten, B., Dannhardt, V., Burr, O., Pöhler, M., Rosengarten, S., Oechsner, M., & Reuter, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101140 · Cited by 32
“However, our data are supported by clinical reports regarding the stroke risk in the different disease processes: Whereas there is a clear indication of an increased cerebrovascular risk in AD, reports on PD are not as conclusive [30–35].”
ResultHishikawa, N., Yamashita, T., Deguchi, K., Wada, J., Shikata, K., Makino, H., & Abe, K. (2014) · European Journal of Neurology · doi:10.1111/ene.12568 · Cited by 30
“However, treatment of VRFs is effective for preventing cognitive decline in AD patients [2,3].”
BackgroundBenefits and Harms of Statins in People with Dementia: A Systematic Review and Meta‐Analysis
Davis, K. A. S., Bishara, D., Perera, G., Molokhia, M., Rajendran, L., & Stewart, R. J. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16342 · Cited by 29
“Table S2 shows the two RCTs(30,31) and three cohort-style studies.(4,32,33) Neither RCT ran for long enough to collect outcomes at 2 years (both were 72 wk) and are therefore only included for adverse events.”
BackgroundLaukka, E. J., Fratiglioni, L., & Bäckman, L. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000313978 · Cited by 32
“A slower progression of the disease would make it possible for those persons diagnosed with AD to stay independent for a longer period. For example, a recent study showed that treatment of VRF was associated with slower decline in MMSE score in patients with AD without CVD [”
ResultCognitive Impairment Is Associated with Medication Nonadherence in Asymptomatic Carotid Stenosis
Kirkpatrick, A. C., Vincent, A. S., Guthery, L. D., & Prodan, C. I. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.08.010 · Cited by 27
Vascular Risk Factors as Treatment Target to Prevent Cognitive Decline
Richard, E., van Charante, E. P. M., & van Gool, W. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120772 · Cited by 29
“In addition, better treatment of vascular risk factors in patients with mildmoderate AD has been reported to be associated with slower cognitive decline [41].”
BackgroundPlatelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Laske, C., Sopova, K., & Stellos, K. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112801784657 · Cited by 27
“On the other hand, vascular risk management including prevention and therapies, that decrease cerebral infarcts is likely to lower the prevalence and progression rate of dementia disorders including AD [11-13].”
BackgroundHess, N., & Smart, N. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00048 · Cited by 28
“Li et al. (2011) observed that the treatment of VRF’s such as hypertension reduced the risk of late-onset AD and the progression from MCI to AD; Deschaintre et al. (2009) also reported that the treatment of VRF’s resulted in slower cognitive decline in individuals with AD.”
ResultSuwa, M., Yamaguchi, S., Komori, T., Kajimoto, S., & Kino, M. (2015) · BioMed Research International · doi:10.1155/2015/153437 · Cited by 30
Chen, S., Fan, C., Chiue, M.-S., Chou, C., Chen, J., & Hseu, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082561 · Cited by 25
Bergland, A. K., Dalen, I., Larsen, A. I., Aarsland, D., & Soennesyn, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160847 · Cited by 27
“Also, one study has suggested that in AD patients without cardiovascular disease, treatment of VRF is associated with a slower decline in MMSE scores [51].”
Youn, H., & Jeong, H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.12.758 · Cited by 25
“1993년 미국 식품의약국(Food and Drug Administration, FDA)에서 최초로 승인된 아세 틸콜린에스테라아제 억제제는 타크린(tacrine)이었으나, 간 독성 문제로 현재는 사용이 제한되고 있다[10].”
Influentialde Oliveira, F. F., Bertolucci, P. H. F., Chen, E. S., & Smith, M. C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215735 · Cited by 23
“Treatment of cerebrovascular risk factors by itself (including hypercholesterolemia) has been associated with slower cognitive decline in AD [46].”
Bampatsias, D., Mavroeidis, I., Tual‐Chalot, S., Vlachogiannis, N. I., Bonini, F., Sachse, M., Mavraganis, G., Mareti, A., Kritsioti, C., Laina, A., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1914-2094 · Cited by 23
“12,13 This evidencestronglysuggestsshared cellular and molecular mechanisms between dementia and atherosclerotic disease.”
Are Vascular Risk Factors Associated With Post-Stroke Depressive Symptoms?
Tennen, G., Herrmann, N., Black, S. E., Levy, K. S., Cappell, J., Li, A., & Lanctôt, K. L. (2011) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988711422526 · Cited by 27
Xiang, J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4661 · Cited by 23
“A previous study revealed that the treatment of vascular risk factors may slow down cognitive decline in patients with AD (44).”
Taşçı, İ., Safer, U., Naharcı, M. İ., Gezer, M., Demir, O., Bozoğlu, E., & Doruk, H. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517724000 · Cited by 23
Can the Treatment of Vascular Risk Factors Slow Cognitive Decline in Alzheimer's Disease Patients?
Richard, F., & Pasquier, F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121012 · Cited by 25
“Consistently, patients in whom some (but not all) VRFs were treated tended to show intermediate decline [86].”
BackgroundSelf-citationCerebrovascular risk factors in early-onset dementia: Table 1
Atkins, E., Bulsara, M. K., & Panegyres, P. K. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.202846 · Cited by 22
“Treatment of vascular risk factors has been associated with slower cognitive decline and reduced risk of AD in older populations.(2) Genetics are important in rare genetically determined autosomal dominant familial patients with AD or frontotemporal dementia (FTD).”
BackgroundWillis, K. J., & Hakim, A. M. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00013 · Cited by 26
“There is also observational data indicating that managing vascular risk factors can slow cognitive decline, even among patients with dementia (Deschaintre et al., 2009).”
BackgroundViswanathan, A., Macklin, E. A., Betensky, R. A., Hyman, B. T., Smith, E. E., & Blacker, D. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000080 · Cited by 24
Translating Current Knowledge Into Dementia Prevention
Román, G. C., Nash, D. T., & Fillit, H. M. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31825cbc4b · Cited by 26
Sekhon, H., Allali, G., & Beauchet, O. (2019) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2019.103932 · Cited by 21
Statins for Treating Alzheimer's Disease: Truly Ineffective?
Liang, T. B., Li, R., & Cheng, O. (2015) · European Neurology · doi:10.1159/000382128 · Cited by 21
Genes influence the amplitude and timing of brain hemodynamic responses
Shan, Z., Vinkhuyzen, A. A. E., Thompson, P. M., McMahon, K. L., Blokland, G. A. M., de Zubicaray, G. I., Calhoun, V. D., Martin, N. G., Visscher, P. M., Wright, M. J., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.09.016 · Cited by 21
“…al., 2010) in Alzheimer’s disease and preliminary evidence suggests that control of vascular risk factors may delay the progression of the disorder (Deschaintre et al., 2009; Richard et al., 2010). variance component being a 50/50 percent mixture of a χ 2 (0) and χ 2 (1) (Dominicus et al., 2006),…”
Statins after ischemic stroke of undetermined etiology in young adults
Putaala, J., Haapaniemi, E., Kaste, M., & Tatlisumak, T. (2011) · Neurology · doi:10.1212/wnl.0b013e318227b1c2 · Cited by 20
Colín-Castelán, D., & Zaina, S. (2019) · Reviews in Endocrine & Metabolic Disorders · doi:10.1007/s11154-019-09486-z · Cited by 19
Shimada, T., Shindo, A., Matsuyama, H., Yata, K., Niwa, A., Sasaki, R., Ayaki, T., Maki, T., Wakita, H., & Tomimoto, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.009 · Cited by 20
Smoking cessation and Alzheimer’s disease: facts, fallacies and promise
Cataldo, J. K., & Glantz, S. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.34 · Cited by 19
“Slowing dementia progression could reduce both the prevalence of AD and the prevalence of later severe stages of AD [21].”
BackgroundVerdelho, A., Biessels, G. J., Chabriat, H., Charidimou, A., Duering, M., Godefroy, O., Pantoni, L., Pavlovic, A. M., & Wardlaw, J. M. (2021) · European Stroke Journal · doi:10.1177/2396987321994294 · Cited by 19
“By comparison, the available evidence specifically concerning treatment of cerebral SVD, the commonest form of vascular brain injury encountered in people with CI, is quite limited.29,39 There clearly is an important potential for vascular prevention strategies in patients with CI.”
BackgroundInfluentialImmune Response at the Crossroads of Atherosclerosis and Alzheimer's Disease
Stahr, N. A., & Galkina, E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.870144 · Cited by 20
“Further strong arguments for an implication of vascular risk factors into AD progression came from a study demonstrating that AD patients that were treated for their vascular risk factors had reduced cognitive decline compared to those that did not receive treatment, despite exclusion of patients with preexisting card…”
ResultDementia Risk Prediction: Are We There Yet?
Kamat, S. M., Kamat, A. S., & Grossberg, G. T. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.12.001 · Cited by 23
Cerebral blood flow and neuropsychological functioning in elderly vascular disease patients
Moser, D. J., Ponto, L. L. B., Miller, I. N., Schultz, S. K., Menda, Y., Arndt, S. V., & Nopoulos, P. (2011) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2011.630653 · Cited by 18
“The existence of common risk factors—that is, hypertension, diabetes, obesity, hyperlipidemia, and apolipoprotein ϵ4 genotype—for both Alzheimer's and vascular dementia ( Iadecola, 2004 ; Naderali, Ratcliffe, & Dale, 2009 ) and the positive effects of the treatment of vascular risk factors on cognitive decline in pati…”
BackgroundConnolly, A., Campbell, S., Gaehl, E., Iliffe, S., Drake, R., Morris, J., Martin, H., & Purandare, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x663046 · Cited by 17
Li, Y., Li, T., Chen, T., Li, C., Yu, W., Xu, Y., Zeng, X., & Zheng, F. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2305091 · Cited by 16
“Tau-mediated mechanisms exacerbate synaptic and neuronal impairments, culminating in cortical dysfunction [24].”
BackgroundCardiovascular Risk and Hippocampal Thickness in Alzheimer’s Disease
Donix, M., Scharf, M., Marschner, K., Werner, A., Sauer, C., Gerner, A., Nees, J. A., Meyer, S., Donix, K. L., von Kummer, R., et al. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/108021 · Cited by 16
“that the treatment of cardiovascular risk factors could slow cognitive decline in Alzheimer’s disease even in the absence of obvious cerebrovascular disease [6].”
BackgroundGui, W., Qiu, C., Shao, Q., & Li, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.617773 · Cited by 17
“35 for the inclusion of the putative VRFs, as previously reported (31, 32).”
MethodRaisi‐Estabragh, Z., M'Charrak, A., McCracken, C., Biasiolli, L., Ardissino, M., Curtis, E., Aung, N., Suemoto, C. K., Mackay, C. E., Suri, S., et al. (2021) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeab075 · Cited by 15
“Indeed, cardiometabolic morbidities have been linked to accelerated cognitive decline(4,5) and their treatment with slowed progression of dementia.(6) Cardiovascular risk factors have been associated with both vascular(7) and Alzheimer’s dementia.”
BackgroundStatins and Cognitive Side Effects
Rojas‐Fernandez, C. H., Hudani, Z., & Bittner, V. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.008 · Cited by 18
Current Management Decisions in Mild Cognitive Impairment
Bensadon, B. A., & Odenheimer, G. L. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.008 · Cited by 18
Qiu, C. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.146 · Cited by 16
Murata, Y., Kadoya, Y., Yamada, S., & Sanke, T. (2016) · Diabetology International · doi:10.1007/s13340-016-0292-9 · Cited by 16
García‐Alberca, J. M., Mendoza, S., Gris, E., Royo, J. L., Cruz-Gamero, J. M., & García‐Casares, N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5366 · Cited by 14
“Furthermore, treatment of VRFs in older patients has been associated with slower cognitive decline and later disease onset.(7) Among these risk factors, hypertension may be the most damaging.”
BackgroundEarly Phase PIB‐PET as a Surrogate for Global and Regional Cerebral Blood Flow Measures
Ponto, L. L. B., Moser, D. J., Menda, Y., Harlynn, E. L., DeVries, S. D., Oleson, J., Magnotta, V. A., & Schultz, S. K. (2018) · Journal of Neuroimaging · doi:10.1111/jon.12582 · Cited by 15
Modeling the Dementia Epidemic
Treves, T. A., & Korczyn, A. D. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00242.x · Cited by 16
“The course of AD can be modified by the presence or absence of vascular risk factors [103] or by their treatment [125].”
BackgroundCardiovascular Risk Management in Persons with Dementia
Nijskens, C. M., Henstra, M. J., Rhodius‐Meester, H. F. M., Yaşar, S., van Poelgeest, E. P., Peters, M. J. L., & Muller, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230019 · Cited by 12
“Also, an observational study evaluating the effect of treatment of vascular risk factors in persons with AD found slower cognitive decline when dyslipidemia was treated [25].”
BackgroundNgwa, J. S., Fungwe, T. V., Ntekim, O. E., Allard, J. S., Johnson, S. M., Castor, C., Graham, L. A., Nadarajah, S., Gillum, R. F., Obisesan, T. O., et al. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000486955 · Cited by 12
Is vascular cognitive impairment a useful concept?
Korczyn, A. D., & Vakhapova, V. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.05.029 · Cited by 12
“Recent data provide evidence that vascular care slows the progression of cognitive impairment in patients diagnosed with AD [7], as well as of white matter lesions in patients with mixed dementia [37].”
Sauze, L., Ha-Vinh, P., & Regnard, P. J. (2011) · Pratiques et Organisation des Soins · doi:10.3917/pos.421.0001 · Cited by 11
Bhattarai, P., Taha, A., Soni, B., Thakuri, D. S., Ritter, E., & Chand, G. B. (2023) · Brain Informatics · doi:10.1186/s40708-023-00213-8 · Cited by 12
“Alzheimer’s disease (AD) is a progressive illness that can start with no noticeable symptoms and advance to severe symptomatic forms [1, 2].”
BackgroundFungwe, T. V., Ngwa, J. S., Ntekim, O. E., Allard, J. S., Nadarajah, S., Wolday, S., Ogunlana, O., Johnson, S. P., Hughes, K., Larbi, D. A., et al. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s195878 · Cited by 12
Hildreth, K. L., Grigsby, J., Bryant, L. L., Wolfe, P., & Baxter, J. (2013) · Journal of Behavioral Medicine · doi:10.1007/s10865-013-9491-z · Cited by 11
“Some studies have suggested that treating cardiovascular risk factors may slow the progression of Alzheimer’s Disease (Deschaintre et al., 2009; Helzner et al., 2009), thus an understanding of how various cardiometabolic risk factors may interact to affect cognitive function is of considerable…”
BackgroundInfluentialTakahashi, M., Oda, Y., Sato, K., & Shirayama, Y. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.17 · Cited by 10
“Importantly, treatment of vascular risk factors has been associated with slower progression of global cognitive decline among AD patients without cerebral vascular disease (27).”
BackgroundReimers-Wessberg, M., Xu, H., Fastbom, J., Seiger, Å., & Eriksdotter, M. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae091 · Cited by 9
Modelling cerebrovascular pathology and the spread of amyloid beta in Alzheimer’s disease
Ahern, A., Thompson, T., Oliveri, H., Lorthois, S., & Goriely, A. (2025) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2024.0548 · Cited by 9
Plant-Based Diets for the Prevention and Treatment of Disabling Diseases
Greger, M. (2015) · American Journal of Lifestyle Medicine · doi:10.1177/1559827615579180 · Cited by 11
Lee, T.-L., Liu, C., Chang, Y.-M., Lin, T.-Y., Chien, C.-Y., Chen, C., Tsai, K., Lin, S., & Sung, P. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190762 · Cited by 8
“ADpatientsmay frequentlyfaceclinicalscenariosofvascularevents at a rate higher than the general population, and a previous study had also suggested that the treatment of vascular risk factors was associated with a slower decline in the progression of AD [27].”
Factors related to continuous and discontinuous attendance at memory clinics
Hishikawa, N., Fukui, Y., Nakano, Y., Morihara, R., Takemoto, M., Sato, K., Yamashita, T., Ohta, Y., & Abe, K. (2017) · European Journal of Neurology · doi:10.1111/ene.13268 · Cited by 7
“medical treatment, such as acetylcholinesterase inhibitors, memantine [12–14] and medications for hypertension, hyperlipidemia and diabetes mellitus [15,16], some patients stop attending hospitals and clinics because of a decline in ADL and/or in cognitive and affective functions, or for other reasons [4,17].”
Wertman, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144202 · Cited by 6
“The CXS features of SLODP open new ways to remedy this assumed irreversible, relentlessly progressive condition [9,79,366–369]: • Treatment of BPCs [50,370] has a direct effect on the recovery of brain parenchyma and cognitive decline (e.g., ischemic penumbra [371]) and on vascular risk factors…”
BackgroundDeguchi, K., Kurata, T., Fukui, Y., Liu, W., Yun, Z., Omote, Y., Sato, K., Kono, S., Hishikawa, N., Yamashita, T., et al. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.06.012 · Cited by 6
Statins and Cognitive Side Effects
Rojas‐Fernandez, C. H., Hudani, Z., & Bittner, V. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.007 · Cited by 6
Lewis, T. J., & Trempe, C. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812112-2.00008-2 · Cited by 6
Hairu, R., Close, J., Lord, S. R., Delbaere, K., Wen, W. X., Jiang, J., & Taylor, M. E. (2021) · Aging & Mental Health · doi:10.1080/13607863.2021.1980859 · Cited by 7
“Reviews analysing the value of treating vascular risk factors in slowing down cognitive decline in people with AD suggested that further research is required, even though some literature supports (Deschaintre et al., 2009; Richard & Pasquier, 2012).”
ResultReduction of Cognitive Decline in Patients with or at High Risk for Diabetes
Maestre, G. E. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0216-y · Cited by 5
Protective Effects of Adaptation to Hypoxia in Experimental Alzheimer’s Disease
Manukhina, E. B., Goryacheva, A. V., Pshennikova, M. G., Malyshev, I. Y., Mallet, R. T., & Downey, H. F. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2906-6_13 · Cited by 6
“A prospective observational study showed that treatment of vascular risk factors in individuals with AD slowed cognitive decline [ 54 ] .”
BackgroundLogroscino, G., Capozzo, R., Tortelli, R., & Marin, B. (2016) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000445410 · Cited by 5
Influence of cognitive impairment on the management of ischaemic stroke
Murao, K., Bombois, S., Cordonnier, C., Hénon, H., Bordet, R., Pasquier, F., & Leys, D. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.01.665 · Cited by 6
Self-citationChanges in Blood Factors and Ultrasound Findings in Mild Cognitive Impairment and Dementia
Cho, K., Kim, J., & Kim, G. W. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00427 · Cited by 5
“Some evidence has suggested that vascular risk factors are associated with the onset and progression of Alzheimer’s disease (AD; Luchsinger et al., 2005; Deschaintre et al., 2009).”
BackgroundDementia risk factors for Australian baby boomers
Panegyres, P. K., & Gray, V. (2010) · Neurology International · doi:10.4081/ni.2010.e13 · Cited by 4
“There seems to be an association between type 2 diabetes and APOEε4 allele, and increased risk of developing AD.39 High Body Mass Index was found to be a significant predictor of dementia indicated by the risk score as per Kivipelto et al.16 Whitmer et al.18 [Neurology International 2010; 2:e13] [page 59] Table 2.”
BackgroundInfluentialAlzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
“[43] However, overzealous correction of vascular risk factors can have a detrimental effect, especially over‑correction of blood pressure.”
Todd, S., McGuinness, B., & Passmore, A. P. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02490.x · Cited by 3
Targeting brain, body and heart for cognitive health and dementia prevention
O’Connor, E. J., & Farrow, M. (2012) · Cited by 12
Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging
Moon, W. (2020) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2020.81.3.488 · Cited by 5
“혈관성 위험인자는 고혈압, 고지혈증, 당뇨, 흡연 및 심혈관질환이 포함된다(18).”
The Relationship between Jaw Function and Cognitive Function in the Elderly Population
Suzuki, K., Kato‐Kogoe, N., Inoue, K., Omori, M., Imagawa, N., Nakano, H., Suwa, Y., Yamamoto, K., Ikehara, S., Kakihana, H., et al. (2020) · Journal of Hard Tissue Biology · doi:10.2485/jhtb.29.169 · Cited by 3
Khan, Q. U. A., & Graff‐Radford, N. R. (2017) · Wiley eBooks · doi:10.1002/9781118661895.ch11 · Cited by 4
Manuel, A. R., Ribeiro, P., Silva, G., Rodrigues, P. M., & Nunes, M. V. S. (2024) · Brain Sciences · doi:10.3390/brainsci14111120 · Cited by 3
“In other words, even after the onset of the disease, lifestyle modification can reduce the rate of cognitive decline [14].”
Alzheimer’s Disease with Vascular Component: A Distinct Clinical Entity
Olazarán, J., Navarro, E. T., & Rojo, J. M. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000342346 · Cited by 4
Sequence variants of the aging gene CISD2 and the risk for Alzheimer's disease
Hsieh, C.-J., Weng, P., Chen, J., Chen, T., Sun, Y., Wen, L., Yip, P., Chu, Y., & Chen, Y. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.02.012 · Cited by 3
“16 AD was determined by the National Institute of Neurological and Communicative Diseases and Stroke d Alzheimer’s Disease and Related Disorders Association criteria for probable AD.”
BackgroundInfluentialCardiac dysfunction and cognitive decline
de la Torre, J. C. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw614 · Cited by 3
“interventions aimed at some of the conditions listed in Figure 1 appear to slow down cognitive decline.(12)”
BackgroundThe Turning Point for Alzheimer’s
de la Torre, J. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-34057-9_16 · Cited by 2
Tsujimoto, M., Suzuki, K., Saji, N., Sakurai, T., Ito, K., Toba, K., & Registry Study Group ORANGE (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220039 · Cited by 2
“In contrast, with treatment, the rate of cognitive decline slowed [62].”
Cho, J., Yoon, C. W., Shin, J., Seo, H., Kim, W., Na, H. K., Byun, J., Lockhart, S. N., Kim, C., Seong, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71402-6 · Cited by 2
Pathophysiology of vascular cognitive impairment
Ihara, M., Okamoto, Y., Takahashi, R., & Tomimoto, H. (2010) · Nosotchu · doi:10.3995/jstroke.32.614 · Cited by 2
Nesteruk, M., Nesteruk, T., Styczyńska, M., & Barcikowska, M. (2015) · Aktualności Neurologiczne · doi:10.15557/an.2015.0003 · Cited by 2
A Tipping Point for Alzheimer’s Disease Research
de la Torre, J. C. (2012) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000e120 · Cited by 2
“2) VRF such as cardiovascular disorders, hypertension, dyslipidemia, atherosclerosis, diabetes type 2, cerebrovascular disease and others [11], are readily diagnosed, can be treated early and could be clinically monitored for long-term changes.”
BackgroundMethodological aspects of constatation of Alzheimer disease as a cause of death in the elderly
Neznanov, N. G., & Kruglov, L. S. (2020) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-4-2-14-18 · Cited by 2
Mixed Dementia in Clinical Trials of Alzheimer's Disease
Massoud, F. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015250 · Cited by 2
Taha, A., Soni, B., Thakuri, D. S., Ritter, E., Bhattarai, P., & Chand, G. B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.25.509432 · Cited by 2
Prevenção do defeito cognitivo e demência - Os factores de risco vascular
Molecular, F. D. M. E. I. D. M., & Verdelho, A. (2010) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v26i1.10712 · Cited by 2
Targeting brain-health from "cradle to grave": Can we prevent or delay dementia?
Shelley, B. P. (2014) · Archives of Medicine and Health Sciences · doi:10.4103/2321-4848.133846 · Cited by 2
“They suggested that dementia should not prevent treatment of multiple VRFs.[35]”
BackgroundAssociation between Cerebral Small Vessel and Alzheimer’s Disease
Lee, K. H., & Kang, K. M. (2022) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2022.0041 · Cited by 2
“과 혈관성 변화가 단순히 고혈압, 고지혈증, 당뇨, 흡연과 같은 혈관성 위험 인자(14)를 공유할 뿐”
van der Veere, P. J., Hoogland, J., Visser, L. N. C., van Harten, A. C., Rhodius‐Meester, H. F. M., Barkhof, F., Teunissen, C. E., van de Giessen, E., Berkhof, J. H., & van der Flier, W. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.082589 · Cited by 1
König, M. (2025) · neuroreha · doi:10.1055/a-2515-6000 · Cited by 1
Mechanosensitive apoptosis in Alzheimer’s disease
Sapozhnikov, G., Ranganathan, R., Wang, S., & Song, Y. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.02 · Cited by 1
van de Haar, H. J. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161110hh · Cited by 2
Hemiparesis followed by dementia
Deschaintre, Y., Massoud, F., & Léger, G. C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997433.009
Self-citationPreserving the Memories: Managing Dementia
Seitz, D. P., Lee, P. E., Gill, S. S., & Rochon, P. A. (2010) · Wiley eBooks · doi:10.1002/9781118281796.ch7
Social Resources That Preserve Functional Independence After Memory Loss
Glymour, M. M., Rist, P. M., & Daniel, J. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada601801
Maladie d’Alzheimer et pathologie cardiovasculaire
Strubel, D. (2011) · Les cahiers de l année gérontologique · doi:10.1007/s12612-010-0170-1
Metadata
- Authors
- Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F.
- Affiliations
- Inserm (FR)
- Venue
- Neurology
- Published
- 2009-09
- Volume
- 73
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986968958
- Cited by
- 232
- References
- 38
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 17 · 2018: 8 · 2017: 14 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 16 · 2012: 22
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, vascular risk factors, cognitive decline, dyslipidemia, diabetes mellitus, smoking, atherosclerosis, cerebrovascular disease, Mini-Mental State Examination, dementia prevention, secondary prevention
- MeSH terms
- Aged, Alzheimer Disease, Hypolipidemic Agents, Cerebral Arteries, Intracranial Arteriosclerosis, Cerebrovascular Disorders, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Risk Factors, Risk Management, Time, Time Factors, Disease Progression, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.